Germany Sees High Bar for Gas Storage Intervention If Goals Missed
If liquefied natural gas supplies keep arriving in the country by the start of November, it may not be appropriate for gas market manager Trading Hub Europe GmbH to step in to support injections, even if the nation's storage goals are missed, according to a memo by the economy ministry seen by Bloomberg. Effectively, Germany is aiming to have storage sites 70% full.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
27 minutes ago
- Fox News
Russia strikes US electronics plant in latest attack on Ukraine
Fox News reporter Stephanie Bennett reports on a new airstrike by Russia that impacted a U.S. electronics plant near the Hungary border on 'Special Report.'
Yahoo
an hour ago
- Yahoo
Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.32%. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.77, delivering a surprise of -50.98%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Oculis Holding AG, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.32 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 28.54%. This compares to year-ago revenues of $0.27 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Oculis Holding AG shares have added about 3.2% since the beginning of the year versus the S&P 500's gain of 8.7%. What's Next for Oculis Holding AG? While Oculis Holding AG has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Oculis Holding AG was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.54 on $0.25 million in revenues for the coming quarter and -$2.44 on $0.82 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Phibro Animal Health (PAHC), another stock in the broader Zacks Medical sector, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 27. This maker of animal health products and nutritional supplements is expected to post quarterly earnings of $0.52 per share in its upcoming report, which represents a year-over-year change of +26.8%. The consensus EPS estimate for the quarter has been revised 1% higher over the last 30 days to the current level. Phibro Animal Health's revenues are expected to be $361.15 million, up 32.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oculis Holding AG (OCS) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Matador (MTDR) Down 8.1% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Matador Resources (MTDR). Shares have lost about 8.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Matador due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Matador Resources Company before we dive into how investors and analysts have reacted as of late. Matador Resources Q2 Earnings Beat on Higher Production Volumes Matador Resources Company reported second-quarter 2025 adjusted earnings of $1.53 per share, which beat the Zacks Consensus Estimate of $1.29. The bottom line declined from the year-ago quarter's $2.05. Total revenues of $895.3 million missed the Zacks Consensus Estimate of $905 million. However, the top line increased from the year-ago quarter's $847.1 million. Better-than-expected quarterly earnings were driven by MTDR's record total production volumes and lower operating expenses. The positives were partially offset by lower commodity price realizations. Upstream Business in Q2 Matador Resources is primarily involved in oil and gas exploration, and production activities in the United States. The company's overall financial performance is heavily dependent on the oil and gas pricing environment. Most of MTDR's production comprises oil (59% of total second-quarter production), making this commodity's price the prime factor in determining the company's earnings. The average daily oil production was 122,875 barrels, reflecting a 0.4% increase from the anticipated figure. The company's record production volumes exceeded the guidance range due to the exceptional performance of both newly commissioned wells and its existing base production. Let us take a look at the average commodity sales price, along with production. Average Sales Price of Commodities The average sales price for oil (without realized derivatives) was $64.34 per barrel, down from $81.20 a year ago. The commodity price was also lower than our projection of $65.55 per barrel. The price of natural gas was $2.05 per thousand cubic feet (Mcf), up from $2 in the year-ago quarter. However, the figure came in lower than our estimate of $3.28 Mcf. Increasing Production Matador reported oil production of 122,875 barrels per day (B/D), up from 95,488 B/D in the prior-year quarter. The figure beat our estimate of 114,908.8 B/D. Natural gas production was recorded at 516.8 million cubic feet per day (MMcf/D), up from 388.9 MMcf/D recorded a year ago. The reported figure surpassed our estimate of 487.3 MMcf/D. The rise in total average production can be attributed to the outperformance of the wells that were brought into production for sales in the last quarter of 2024. Total oil equivalent production in the second quarter was 209,013 BOE/D, reflecting a 30.4% increase from the year-ago quarter's 160,305 BOE/D. The figure was also above our projection of 206,955.1 BOE/D. Operating Expenses MTDR's plant and other midstream services' operating expenses decreased to $2.40 per BOE from the year-earlier level of $2.55. Our estimate for the same was pinned at $2.68. Lease operating costs increased to $5.56 per BOE from $5.42 a year ago. Our projection for the metric was pinned at $5.45 per BOE. Production taxes, transportation and processing costs declined to $4.35 per BOE from $5.27 in the year-ago quarter. Our projection for the metric was pinned at $5.31 per BOE. Overall, total operating expenses per BOE were $29.91, lower than the prior-year figure of $30.64 and also below our estimate of $30.54. Balance Sheet & Capital Spending As of June 30, 2025, MTDR had cash and restricted cash of $86.8 million and a long-term debt of $3,286 million. In the second quarter, the company spent $367.1 million on well drilling, completion and equipment. Outlook For 2025, Matador Resources expects average daily oil equivalent production to be 200,000-205,000 Boe/d. This implies a 1.3% increase from its previous guidance. The company also expects average daily total production for the third quarter of 2025 to be 198,500-201,000 Boe/d. The company has also reiterated its total 2025 capital expenditure forecast of $1.30-$1.55 billion. How Have Estimates Been Moving Since Then? In the past month, investors have witnessed a downward trend in estimates revision. VGM Scores At this time, Matador has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. However, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Outlook Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Matador has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Matador Resources Company (MTDR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
